ASX growth shares increasing in size quickly could be contenders for an investor’s portfolio.
There is growing volatility in the ASX share market. This may open up some better value opportunities for people to find.
Share prices regularly change, but lower prices give the chance getting exposure to quality companies at the best prices.
Here are two of them:
Doctor Care Anywhere Group PLC (ASX: DOC)
Doctor Care Anywhere is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways on its platform. It has relationships with health insurers, healthcare providers and corporate customers to connect with a range of telehealth services.
It also recently completed the acquisition of Australian telehealth and tele-mental provider GP2U Telehealth. This gives the business another avenue for growth and geographical diversification. The ASX growth share has also entered the self-pay market in the Republic of Ireland through its channel partner Boots.
It’s expecting to report 2021 revenue growth of at least 100% compared to FY20, excluding the acquisition.
The three months to 30 September 2021 saw growth with a number of metrics. Quarter on quarter revenue growth was 21.6% to AU$10.7 million. Consultations grew by 30.6% to 116,800 with over 65% of consultations delivered to returning patients.
Activated lives reached 603,200 during the quarter – up 8% quarter on quarter. An activated life is the total number of people who have signed up for Doctor Care Anywhere’s service and entered their personal details.
Volpara Health Technologies Ltd (ASX: VHT)
Volpara describes itself as a health technology software company with an integrated platform which assists in the delivery of personalised breast care.
The ASX growth share grew its subscription revenue by 35% to NZ$11.8 million in the first half of FY22. Its revenue comes with a very high gross profit margin of 91.4%.
Its market share of women who have at least one Volpara product used on their image is around 34%.
Volpara says that its strategic commercial partnerships will help it achieve greater reach in not only genetic testing for breast cancer but expansion into the US lung cancer market where AI and software offer the prospect of saving many more lives.
It has partnered with a number of different organisations, including in lung, with RevealDx, Riverain Technologies, Natera and Invitae.
The company has a number of areas of focus for growth such as expanding the electronic health record (EHR) sales channel. It’s also working on building its data platform in a key effort to change from screening for detection to prevention.
It’s expecting to reach revenue of between NZ$25 million to NZ$26 million in this financial year.
Volpara management said the next few months is going to be “incredibly busy and exciting” as it heads to Chicago for the large radiology conference RSNA. The third and fourth quarters of the year are traditionally the biggest quarters for the business.